PARVB (parvin beta) is an adapter protein that functions primarily in integrin signaling and cytoskeletal regulation. PARVB localizes to focal adhesions and plays a crucial role in cell adhesion, spreading, motility, and survival through interactions with partners including integrin-linked kinase (ILK), paxillin, and alpha-actinin 1. Unlike its family member PARVA, PARVB promotes cell spreading by binding alphaPIX and alpha-actinin, while inhibiting ILK activity and reversing some oncogenic effects in cancer cells 1. The protein is involved in actin cytoskeleton reorganization and lamellipodia formation through activation of GTPases CDC42 and RAC1 1. In disease contexts, PARVB demonstrates complex roles: it contributes to cancer metastasis through the ILK-β-parvin pathway when activated by NET-DNA via the CCDC25 receptor 2, and promotes immunosuppression in cervical cancer by activating SMAD signaling and upregulating TNFSF13 to drive M2 macrophage polarization 3. Conversely, PARVB deficiency protects against cisplatin-induced kidney injury by promoting TAK1 degradation through ITCH-dependent ubiquitination 4. PARVB variants are associated with nonalcoholic fatty liver disease severity in children and serve as prognostic markers in hematological malignancies 567.